Anticoagulation Forum/LinkedIn
Sep 5, 2025, 12:55
RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
Anticoagulation Forum shared on LinkedIn:
”Missed it live? The recording of our recent webinar ‘Secondary VTE Prevention: To Reduce or Not to Reduce? A Focus on RENOVE and API-CAT‘ is now available!
Watch it now on our Archived Webinars page.
Dive into one of the most debated questions in anticoagulation—when and how to reduce the dose.
Our expert panel breaks down results from the RENOVE and API-CAT trials, with practical insights you can apply in your practice right away.
What you’ll take away:
- DOAC dosing strategies for extended secondary VTE prevention
- Evidence-based guidance for individualized care
- Real-world tips from leading clinicians
Free for AC Forum members — and joining is quick and free.
Don’t miss the chance to catch up on this timely and dynamic discussion!”
Watch the webinar here.
Find the latest webinars and seminars on thrombosis featured in Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines